CXCL9 and melanoma: Their study included data from patients with advanced melanoma, renal cell, lung, urothelial or colorectal cancer and highlighted the predictive role of tumor-cell intrinsic parameters (e.g., tumor mutational burden) as well as parameters related to the immune microenvironment (e.g., CXCL9, CD8A, CXCL13)41.